# AMIX (Autonomix Medical, Inc.) - SEC EDGAR Financial Statements

> Autonomix Medical, Inc. reported $0 in revenue and a net loss of $11.78M for the trailing twelve months ended September 30, 2026.

- Canonical: https://convexityos.com/fundamentals/AMIX
- Markdown: https://convexityos.com/fundamentals/AMIX.md
- SEC CIK: 0001617867
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:13 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001617867&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $0 | Sep 30, 2026 |
| Operating Income | TTM | -$12.03M | Operating profit |
| Net Income | TTM | -$11.78M | GAAP bottom line |
| Diluted EPS | TTM | -- | Split-adjusted |
| Free Cash Flow | TTM | -$12.29M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $7.69M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 |
| Research & Development | $7.14M | $4.72M | $2.23M | $745K |
| Total Operating Expenses | $17.03M | $11.59M | $12.03M | $1.99M |
| **Operating Income** | -$17.03M | -$11.59M | -$12.03M | -$1.99M |
| **EBITDA** | -$17.02M | -$11.40M | -$11.95M | -$1.99M |
| Interest Income | $319K | $354K | $127K | $0 |
| Interest Expense | $0 | $176K | $79K | $0 |
| Income Before Tax | -$16.71M | -$11.41M | -$15.43M | -$1.99M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| **Net Income** | -$16.71M | -$11.41M | -$15.43M | -$1.99M |
| Basic EPS | -$2.33 | -$6.49 | -$229.76 | -$35.57 |
| Basic Shares Outstanding | 7.2M | 1.8M | 67.1K | 57.5K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & Development | $1.58M | $1.51M | $1.46M | $1.72M | $2.37M | $1.59M | $1.55M | $1.04M |
| Total Operating Expenses | $3.18M | $2.77M | $2.74M | $3.34M | $7.53M | $3.42M | $3.25M | $2.75M |
| **Operating Income** | -$3.18M | -$2.77M | -$2.74M | -$3.34M | -$7.53M | -$3.42M | -$3.25M | -$2.75M |
| **EBITDA** | -$3.17M | -$2.77M | -$2.73M | -$3.34M | -$7.53M | -$3.42M | -$3.07M | -$2.70M |
| Interest Income | $51K | $42K | $71K | $82K | $83K | $84K | $107K | $80K |
| Interest Expense | -- | -- | $0 | $0 | $0 | $0 | $46K | $45K |
| Income Before Tax | -$3.13M | -$2.73M | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.19M | -$2.71M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$3.13M | -$2.73M | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$11.41M | -$2.71M |
| Basic EPS | -$2.51 | -$5.02 | -- | -$0.36 | -$29.02 | -$22.69 | -- | -$1.47 |
| Basic Shares Outstanding | 1.2M | 543.7K | -- | 8.9M | 256.7K | 147.1K | -- | 1.8M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.00M | $9.14M | $8.61M | $865K |
| **Cash & Short-Term Investments** | $7.00M | $9.14M | $8.61M | $865K |
| Other Current Assets | $577K | $473K | $783K | $0 |
| **Total Current Assets** | $7.58M | $9.61M | $9.39M | $865K |
| Property, Plant & Equipment, Net | $19K | $21K | $16K | $0 |
| **Total Non-Current Assets** | $19K | $197K | $16K | $0 |
| **Total Assets** | $7.60M | $9.81M | $9.41M | $865K |
| Accounts Payable | $700K | $676K | $492K | $173K |
| Short-Term Debt | -- | -- | $0 | -- |
| **Total Current Liabilities** | $1.71M | $1.71M | $777K | $221K |
| Long-Term Debt | -- | -- | -- | $0 |
| Other Non-Current Liabilities | -- | -- | -- | $0 |
| **Total Non-Current Liabilities** | $0 | $0 | $1.00M | $0 |
| **Total Liabilities** | $1.71M | $1.71M | $1.78M | $221K |
| **Total Debt (incl. Leases)** | -- | -- | $0 | $0 |
| Common Stock | $1.0K | $2.0K | $1.0K | $12K |
| Retained Earnings | -$67.09M | -$50.38M | -$38.97M | -$23.54M |
| **Total Stockholders' Equity** | $5.89M | $8.10M | $7.63M | $644K |
| Total Equity | $5.89M | $8.10M | $7.63M | $644K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.69M | $3.46M | $7.00M | $9.93M | $7.48M | $8.59M | $9.14M | $11.82M |
| **Cash & Short-Term Investments** | $7.69M | $3.46M | $7.00M | $9.93M | $7.48M | $8.59M | $9.14M | $11.82M |
| Other Current Assets | $484K | $504K | $577K | $257K | $416K | $389K | $473K | $109K |
| **Total Current Assets** | $8.18M | $3.96M | $7.58M | $10.19M | $7.89M | $8.98M | $9.61M | $11.93M |
| Property, Plant & Equipment, Net | $19K | $16K | $19K | $20K | $16K | $19K | $21K | $20K |
| **Total Non-Current Assets** | $19K | $16K | $19K | $20K | $39K | $19K | $197K | $20K |
| **Total Assets** | $8.20M | $3.98M | $7.60M | $10.21M | $7.93M | $9.00M | $9.81M | $11.95M |
| Accounts Payable | $630K | $371K | $700K | $714K | $842K | $815K | $676K | $232K |
| Short-Term Debt | -- | -- | -- | -- | -- | -- | -- | $1.13M |
| **Total Current Liabilities** | $1.25M | $818K | $1.71M | $1.65M | $1.49M | $1.97M | $1.71M | $2.25M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $1.25M | $818K | $1.71M | $1.65M | $1.49M | $1.97M | $1.71M | $2.25M |
| **Total Debt (incl. Leases)** | -- | -- | -- | -- | -- | -- | -- | $1.13M |
| Common Stock | $2.0K | $1.0K | $1.0K | $11K | $6.0K | $4.0K | $2.0K | $2.0K |
| Retained Earnings | -$72.95M | -$69.82M | -$67.09M | -$64.43M | -$61.17M | -$53.72M | -$50.38M | -$47.19M |
| **Total Stockholders' Equity** | $6.94M | $3.16M | $5.89M | $8.56M | $6.45M | $7.03M | $8.10M | $9.71M |
| Total Equity | $6.94M | $3.16M | $5.89M | $8.56M | $6.45M | $7.03M | $8.10M | $9.71M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- | --- |
| Net Income | -$16.71M | -$11.41M | -$15.43M | -$1.99M |
| Depreciation & Amortization | $12K | $183K | $81K | $0 |
| Stock-Based Compensation | $529K | $1.63M | $618K | $0 |
| Change in Payables | $24K | $184K | $320K | $81K |
| **Operating Cash Flow** | -$12.28M | -$8.26M | -$6.60M | -$1.85M |
| Capital Expenditure | -$10K | -$14K | -$19K | $0 |
| **Free Cash Flow** | -$12.29M | -$8.27M | -$6.62M | -$1.85M |
| **Investing Cash Flow** | -$10K | -$14K | -$19K | $0 |
| Common Stock Issued | $0 | $2.0K | $2.84M | $675K |
| **Financing Cash Flow** | $10.16M | $8.80M | $14.41M | $675K |
| **Net Change in Cash** | -$2.13M | $528K | $7.74M | -$1.18M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$3.13M | -$2.73M | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$11.41M | -$2.71M |
| Depreciation & Amortization | $4.0K | $3.0K | $3.0K | $4.0K | $2.0K | $3.0K | $183K | $47K |
| Stock-Based Compensation | $53K | $2.0K | $1.0K | $2.0K | $138K | $388K | $1.63M | $418K |
| Change in Payables | $176K | -$329K | $22K | -$164K | $26K | $140K | $184K | -$342K |
| **Operating Cash Flow** | -$2.61M | -$3.54M | -$2.89M | -$2.97M | -$3.82M | -$2.60M | -$8.26M | -$2.30M |
| Capital Expenditure | -- | -- | -$3.0K | -$7.0K | $0 | $0 | -$14K | -$5.0K |
| **Free Cash Flow** | -- | -- | -$2.90M | -$2.98M | -$3.82M | -$2.60M | -$8.27M | -$2.31M |
| **Investing Cash Flow** | -- | -- | -$3.0K | -$7.0K | $0 | $0 | -$14K | -$5.0K |
| Common Stock Issued | -- | $0 | -- | -- | -- | $2.12M | $2.0K | $0 |
| **Financing Cash Flow** | $6.85M | $0 | -$35K | $5.43M | $2.71M | $2.06M | $8.80M | $8.97M |
| **Net Change in Cash** | $4.23M | -$3.54M | -$2.93M | $2.46M | -$1.11M | -$547K | $528K | $6.67M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -283.5% | -140.9% | -202.2% | -309.0% |
| Return on Assets (ROA) | -219.9% | -116.4% | -164.0% | -230.1% |
| Current Ratio | 4.45x | 5.63x | 12.09x | 3.91x |
| Quick Ratio | 4.11x | 5.35x | 11.08x | 3.91x |
| Debt to Equity | -- | -- | 0.00x | 0.00x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -169.7% | -509.4% | -283.5% | -297.4% | -386.5% | -288.2% | -242.4% | -243.6% |
| Return on Assets (ROA) | -143.8% | -404.7% | -219.9% | -249.3% | -314.0% | -225.3% | -200.2% | -197.8% |
| Current Ratio | 6.52x | 4.85x | 4.45x | 6.18x | 5.31x | 4.57x | 5.63x | 5.31x |
| Quick Ratio | 6.13x | 4.23x | 4.11x | 6.02x | 5.03x | 4.37x | 5.35x | 5.27x |
| Debt to Equity | -- | -- | -- | -- | -- | -- | -- | 0.12x |

## Related Companies

[ALXO (Alx Oncology Holdings Inc.)](https://convexityos.com/fundamentals/ALXO), [AMLX (Amylyx Pharmaceuticals, Inc.)](https://convexityos.com/fundamentals/AMLX), [ALTB (Alpine Auto Brokers Inc.)](https://convexityos.com/fundamentals/ALTB), [ANVS (Annovis Bio, Inc.)](https://convexityos.com/fundamentals/ANVS), [ALPE (Alpha-en Corporation)](https://convexityos.com/fundamentals/ALPE), [APHD (Verde Bio Holdings, Inc.)](https://convexityos.com/fundamentals/APHD), [ALLO (Allogene Therapeutics, Inc.)](https://convexityos.com/fundamentals/ALLO), [APSI (Aqua Power Systems Inc.)](https://convexityos.com/fundamentals/APSI)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
